MX2010001593A - Nuevos derivados de 6-triazolopiridazina-sulfanil benzotiazol y bencimidazol, su proceso de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y nuevo uso principalmente como inhibidores de met. - Google Patents
Nuevos derivados de 6-triazolopiridazina-sulfanil benzotiazol y bencimidazol, su proceso de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y nuevo uso principalmente como inhibidores de met.Info
- Publication number
- MX2010001593A MX2010001593A MX2010001593A MX2010001593A MX2010001593A MX 2010001593 A MX2010001593 A MX 2010001593A MX 2010001593 A MX2010001593 A MX 2010001593A MX 2010001593 A MX2010001593 A MX 2010001593A MX 2010001593 A MX2010001593 A MX 2010001593A
- Authority
- MX
- Mexico
- Prior art keywords
- phenyl
- novel
- medicaments
- triazolopyridazinesulfanyl
- benzothiazole
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 title 2
- 229940058303 antinematodal benzimidazole derivative Drugs 0.000 title 1
- 125000003785 benzimidazolyl group Chemical class N1=C(NC2=C1C=CC=C2)* 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 4
- 125000003545 alkoxy group Chemical group 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 3
- -1 O-cycloalkyl Chemical group 0.000 abstract 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 2
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Abstract
La invención se refiere a productos nuevos de fórmula (I): en donde ··· representa un enlace sencillo o doble; Ra representa H, Hal. alcoxi. O-cicloalquilo, heteroarilo, fenilo, NHCOaIk, NHCOcicloalk o NR1R2; X representa S, SO o SO2, A representa NH o S; W representa H, alquilo o COR con R que representa cicloalquilo; alquilo sustituido opcionalmente con NR3R4, alcoxi, hidroxi, fenilo, heteroarilo o heterocicloalquilo; alcoxi sustituido opcionalmente con NR3R4, es decir un radical O-(CH2)n-NR3R4, un radical O-fenilo o O-(CH2)n-fenilo, con fenilo sustituido opcionalmente y n = 1 a 4: o el radical NR1R2 ; R1 representa H o alk y R2 representa H, cicloalquilo o alquilo; R3 y R4 representan H, alk. cicloalquilo, heteroarilo o fenilo; R1,R2 y/o R3,R4 forman con N un ciclo que contiene opcionalmente O, S, N y/o NH, estando todos tos heterocicloalquilo, heteroarilo y fenilo y cíclicos sustituidos opcionalmente; estando estos productos en todas las formas isómeras y las sales, como medicamentos principalmente como inhibidores de MET.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0705789A FR2919870B1 (fr) | 2007-08-09 | 2007-08-09 | Nouveaux derives de 6-triazolopyridazine-sulfanyl benzothiazole et benzothiazole et benzimidazole, procede, compositions pharmaceutiques et nouvelle utilisation comme inhibiteurs de cmet |
| FR0801819A FR2929613B1 (fr) | 2008-04-02 | 2008-04-02 | Nouveaux derives de 6-triazolopyridazine-sulfanyl benzothiazole et benzimidazole,leur preparation,comme medicaments et utilisation notamment comme inhibiteurs de met |
| PCT/FR2008/001172 WO2009056692A2 (fr) | 2007-08-09 | 2008-08-06 | Nouveaux derives de 6-triazolopyridazine-sulfanyl benzothiazole et benzimidazole, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de met |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2010001593A true MX2010001593A (es) | 2010-10-04 |
Family
ID=40524792
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2010001593A MX2010001593A (es) | 2007-08-09 | 2008-08-06 | Nuevos derivados de 6-triazolopiridazina-sulfanil benzotiazol y bencimidazol, su proceso de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y nuevo uso principalmente como inhibidores de met. |
| MX2014000226A MX340060B (es) | 2007-08-09 | 2008-08-06 | Nuevos derivados de 6-triazolopiridazina-sulfanil benzotiazol y bencimidazol, su proceso de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y nuevo uso principalmente como inhibidores de met. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014000226A MX340060B (es) | 2007-08-09 | 2008-08-06 | Nuevos derivados de 6-triazolopiridazina-sulfanil benzotiazol y bencimidazol, su proceso de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y nuevo uso principalmente como inhibidores de met. |
Country Status (41)
| Country | Link |
|---|---|
| US (3) | US8546393B2 (es) |
| EP (1) | EP2178881B1 (es) |
| JP (1) | JP5694767B2 (es) |
| KR (1) | KR101654376B1 (es) |
| CN (1) | CN101801973B (es) |
| AR (1) | AR068055A1 (es) |
| AU (1) | AU2008320791B2 (es) |
| BR (1) | BRPI0815606A2 (es) |
| CA (2) | CA2884102A1 (es) |
| CL (1) | CL2008002351A1 (es) |
| CO (1) | CO6251270A2 (es) |
| CR (1) | CR11252A (es) |
| CY (1) | CY1114906T1 (es) |
| DK (1) | DK2178881T3 (es) |
| DO (1) | DOP2010000040A (es) |
| EA (1) | EA023465B1 (es) |
| EC (1) | ECSP109944A (es) |
| ES (1) | ES2436657T3 (es) |
| GT (1) | GT201000023A (es) |
| HR (1) | HRP20131182T1 (es) |
| IL (1) | IL203734A (es) |
| JO (1) | JO2935B1 (es) |
| MA (1) | MA31685B1 (es) |
| ME (1) | ME00972B (es) |
| MX (2) | MX2010001593A (es) |
| MY (1) | MY152535A (es) |
| NI (1) | NI201000022A (es) |
| NZ (1) | NZ583177A (es) |
| PA (1) | PA8792501A1 (es) |
| PE (1) | PE20090900A1 (es) |
| PL (1) | PL2178881T3 (es) |
| PT (1) | PT2178881E (es) |
| RS (1) | RS53078B (es) |
| SG (1) | SG183077A1 (es) |
| SI (1) | SI2178881T1 (es) |
| TN (1) | TN2010000026A1 (es) |
| TW (1) | TWI429649B (es) |
| UA (1) | UA101328C2 (es) |
| UY (1) | UY31277A1 (es) |
| WO (1) | WO2009056692A2 (es) |
| ZA (1) | ZA201000912B (es) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PA8792501A1 (es) | 2007-08-09 | 2009-04-23 | Sanofi Aventis | Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol,su procedimiento de preparación,su aplicación como medicamentos,composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met. |
| AU2009272516A1 (en) * | 2008-07-18 | 2010-01-21 | Sanofi-Aventis | Novel triazolo(4,3-a)pyridine derivatives, process for the preparation thereof, use thereof as medicaments, pharmaceutical compositions and novel use, in particular as MET inhibitors |
| EA201170223A1 (ru) * | 2008-07-18 | 2011-08-30 | Санофи-Авентис | НОВЫЕ ПРОИЗВОДНЫЕ ИМИДАЗО[1,2-a]ПИРИДИНА, СПОСОБ ИХ ПОЛУЧЕНИЯ, ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ЛЕКАРСТВЕННЫХ СРЕДСТВ, ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ И НОВОЕ ПРИМЕНЕНИЕ, В ЧАСТНОСТИ, В КАЧЕСТВЕ ИНГИБИТОРОВ МЕТ |
| FR2941229B1 (fr) * | 2009-01-21 | 2012-11-30 | Sanofi Aventis | Nouveaux derives triazolo°4,3-a!pyridine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de met |
| FR2945806B1 (fr) * | 2009-05-19 | 2013-04-05 | Sanofi Aventis | Nouveaux derives imidazo[1,2-a]pyridine,procede de preparation,medicaments,compositions pharmaceutiques et utilisation notamment comme inhibiteurs de met |
| UY32049A (es) | 2008-08-14 | 2010-03-26 | Takeda Pharmaceutical | Inhibidores de cmet |
| FR2941951B1 (fr) * | 2009-02-06 | 2011-04-01 | Sanofi Aventis | Derives de 6-(6-nh-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met. |
| FR2941952B1 (fr) * | 2009-02-06 | 2011-04-01 | Sanofi Aventis | Derives de 6-(6-substitue-triazolopyridazine-sulfanyl) 5-fluoro-benzothiazoles et 5-fluoro-benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met. |
| FR2941949B1 (fr) * | 2009-02-06 | 2011-04-01 | Sanofi Aventis | Derives de 6-(6-o-cycloalkyl ou 6-nh-cycloalkyl- triazolopyridazine-sulfanyl)benzothiazoles et benzimidazoles preparation, application comme medicaments et utilisation comme inhibiteurs de met. |
| FR2941950B1 (fr) * | 2009-02-06 | 2011-04-01 | Sanofi Aventis | Derives de 6-(6-o-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met. |
| CN102388048B (zh) * | 2009-02-10 | 2014-07-30 | 阿斯利康(瑞典)有限公司 | 三唑并[4，3-b]哒嗪衍生物及其用于前列腺癌的用途 |
| EA201101604A1 (ru) * | 2009-05-11 | 2012-05-30 | Астразенека Аб | [1,2,4]триазоло[4,3-b]пиридазины в качестве лигандов андрогенового рецептора |
| ES2840454T3 (es) | 2009-12-31 | 2021-07-06 | Hutchison Medipharma Ltd | Intermedio sintético útil en la preparación de inhibidores de c-Met triazolopiridínicos |
| WO2011121223A1 (fr) | 2010-03-30 | 2011-10-06 | Sanofi-Aventis | Derives de 6-(alkyl- ou cycloalkyl-triazolopyridazine-sulfanyl) benzothiazoles: preparation, application comme medicaments et utilisation comme inhibiteurs de met |
| FR2958292A1 (fr) * | 2010-03-30 | 2011-10-07 | Sanofi Aventis | Derives de 6-(alkyl- ou cycloalkyl-triazolopyridazine-sulfanyl) benzothiazoles: preparation, application comme medicaments et utilisation comme inhibiteurs de met |
| FR2966151B1 (fr) * | 2010-10-14 | 2012-11-09 | Sanofi Aventis | Derives de 6-(alkyl- ou cycloalkyl-triazolopyridazine-sulfanyl) benzothiazoles: preparation, application comme medicaments et utilisation comme inhibiteurs de met |
| WO2012003338A1 (en) | 2010-07-01 | 2012-01-05 | Takeda Pharmaceutical Company Limited | COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET |
| AR085183A1 (es) | 2010-07-30 | 2013-09-18 | Lilly Co Eli | Compuesto 6-(1-metil-1h-pirazol-4-il)-3-(2-metil-2h-indazol-5-iltio)-[1,2,4]triazol[4,3-b]piridazina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar cancer |
| UA117092C2 (uk) | 2011-09-06 | 2018-06-25 | Байєр Інтеллектуал Проперті Гмбх | Амінозаміщені імідазопіридазини |
| EP2755976B1 (en) | 2011-09-15 | 2018-07-18 | Novartis AG | 6-substituted 3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyridines as c-met tyrosine kinase inhibitors |
| CN104470500A (zh) | 2012-07-12 | 2015-03-25 | 赛诺菲 | 包含1-(6-{[6-(4-氟苯基)[1,2,4]三唑并[4,3-b]哒嗪-3-基]硫基}-1,3-苯并噻唑-2-基)-3-(2-吗啉-4-基乙基)尿素化合物的抗肿瘤组合物 |
| WO2014076162A1 (en) | 2012-11-19 | 2014-05-22 | Bayer Pharma Aktiengesellschaft | Aminoimidazopyridazines |
| TWI695837B (zh) | 2014-12-04 | 2020-06-11 | 比利時商健生藥品公司 | 作為激酶調節劑之三唑並嗒 |
| EP3229836B1 (en) | 2014-12-09 | 2019-11-13 | Institut National de la Sante et de la Recherche Medicale (INSERM) | Human monoclonal antibodies against axl |
| WO2016135041A1 (en) | 2015-02-26 | 2016-09-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Fusion proteins and antibodies comprising thereof for promoting apoptosis |
| US10047071B1 (en) | 2018-01-15 | 2018-08-14 | King Saud University | Dihydropyrimidinone derivatives |
| CN110317216A (zh) * | 2018-03-28 | 2019-10-11 | 首都医科大学 | 一种三唑并哒嗪类衍生物在医药领域的应用 |
| KR20210142154A (ko) | 2019-03-21 | 2021-11-24 | 옹쎄오 | 암 치료를 위한 키나제 억제제와 조합된 dbait 분자 |
| CN110041311B (zh) * | 2019-05-20 | 2021-03-19 | 东南大学 | 一种荧光探针分子ml-fp及其制备方法和应用 |
| CN114174284A (zh) * | 2019-06-12 | 2022-03-11 | 百时美施贵宝公司 | 6-(环丙烷甲酰胺基)-4-((2-甲氧基-3-(1-甲基-1H-1,2,4-三唑-3-基)苯基)氨基)-N-(甲基-d3)哒嗪-3-甲酰胺的结晶盐形式 |
| CN114761006A (zh) | 2019-11-08 | 2022-07-15 | Inserm(法国国家健康医学研究院) | 对激酶抑制剂产生耐药性的癌症的治疗方法 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| AU2024241633A1 (en) | 2023-03-30 | 2025-11-06 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| WO2024229406A1 (en) | 2023-05-04 | 2024-11-07 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| WO2025034702A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Rmc-6291 for use in the treatment of ras protein-related disease or disorder |
| TW202530228A (zh) | 2023-10-12 | 2025-08-01 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2499995A1 (fr) | 1981-02-13 | 1982-08-20 | Roussel Uclaf | Nouvelles oximes derivees de l'acide 3-alkyloxy ou 3-alkylthiomethyl 7-amino thiazolylacetamido cephalosporanique, leur preparation, leur application comme medicaments, les compositions les renfermant et les nouveaux intermediaires obtenus. |
| AU773567B2 (en) * | 1998-09-11 | 2004-05-27 | Warner-Lambert Company | HIV protease inhibitors |
| EP1298125A1 (en) | 2001-09-26 | 2003-04-02 | Aventis Pharma S.A. | Substituted benzimidazole compounds and their use for the treatment of cancer |
| MX2008007049A (es) * | 2005-11-30 | 2008-10-23 | Vertex Pharma | Inhibidores de c-met y usos de los mismos. |
| DK1966214T3 (en) * | 2005-12-21 | 2017-02-13 | Janssen Pharmaceutica Nv | TRIAZOLPYRIDAZINES AS TYROSINKINASA MODULATORS |
| CA2651979A1 (en) * | 2006-05-30 | 2007-12-06 | Pfizer Products Inc. | Triazolopyridazine derivatives |
| PE20121506A1 (es) * | 2006-07-14 | 2012-11-26 | Amgen Inc | Compuestos triazolopiridinas como inhibidores de c-met |
| KR20090071612A (ko) * | 2006-10-23 | 2009-07-01 | 에스지엑스 파마슈티컬스, 인코포레이티드 | 단백질 키나제 조정제로서의 바이시클릭 트리아졸 |
| PA8792501A1 (es) | 2007-08-09 | 2009-04-23 | Sanofi Aventis | Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol,su procedimiento de preparación,su aplicación como medicamentos,composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met. |
-
2008
- 2008-08-05 PA PA8792501A patent/PA8792501A1/es unknown
- 2008-08-06 HR HRP20131182AT patent/HRP20131182T1/hr unknown
- 2008-08-06 JP JP2010519489A patent/JP5694767B2/ja not_active Expired - Fee Related
- 2008-08-06 DK DK08845285T patent/DK2178881T3/da active
- 2008-08-06 UA UAA201002523A patent/UA101328C2/uk unknown
- 2008-08-06 MY MYPI2010000582A patent/MY152535A/en unknown
- 2008-08-06 BR BRPI0815606 patent/BRPI0815606A2/pt active Search and Examination
- 2008-08-06 EP EP08845285.9A patent/EP2178881B1/fr active Active
- 2008-08-06 SI SI200831106T patent/SI2178881T1/sl unknown
- 2008-08-06 PT PT08845285T patent/PT2178881E/pt unknown
- 2008-08-06 SG SG2012055091A patent/SG183077A1/en unknown
- 2008-08-06 NZ NZ583177A patent/NZ583177A/en not_active IP Right Cessation
- 2008-08-06 RS RSP20130542 patent/RS53078B/sr unknown
- 2008-08-06 EA EA201070235A patent/EA023465B1/ru not_active IP Right Cessation
- 2008-08-06 MX MX2010001593A patent/MX2010001593A/es active IP Right Grant
- 2008-08-06 MX MX2014000226A patent/MX340060B/es unknown
- 2008-08-06 ME MEP-2010-7A patent/ME00972B/me unknown
- 2008-08-06 PL PL08845285T patent/PL2178881T3/pl unknown
- 2008-08-06 KR KR1020107005087A patent/KR101654376B1/ko not_active Expired - Fee Related
- 2008-08-06 AU AU2008320791A patent/AU2008320791B2/en not_active Ceased
- 2008-08-06 CN CN200880106250.6A patent/CN101801973B/zh not_active Expired - Fee Related
- 2008-08-06 CA CA2884102A patent/CA2884102A1/fr not_active Abandoned
- 2008-08-06 CA CA2695628A patent/CA2695628C/fr not_active Expired - Fee Related
- 2008-08-06 WO PCT/FR2008/001172 patent/WO2009056692A2/fr not_active Ceased
- 2008-08-06 ES ES08845285T patent/ES2436657T3/es active Active
- 2008-08-07 TW TW97130120A patent/TWI429649B/zh not_active IP Right Cessation
- 2008-08-07 PE PE2008001322A patent/PE20090900A1/es not_active Application Discontinuation
- 2008-08-07 JO JO2008361A patent/JO2935B1/en active
- 2008-08-07 AR ARP080103452 patent/AR068055A1/es unknown
- 2008-08-08 UY UY31277A patent/UY31277A1/es not_active Application Discontinuation
- 2008-08-08 CL CL2008002351A patent/CL2008002351A1/es unknown
-
2010
- 2010-01-13 TN TNP2010000026A patent/TN2010000026A1/fr unknown
- 2010-01-26 US US12/693,736 patent/US8546393B2/en not_active Expired - Fee Related
- 2010-01-28 GT GT201000023A patent/GT201000023A/es unknown
- 2010-01-28 DO DO2010000040A patent/DOP2010000040A/es unknown
- 2010-01-29 CO CO10009506A patent/CO6251270A2/es active IP Right Grant
- 2010-02-03 NI NI201000022A patent/NI201000022A/es unknown
- 2010-02-03 CR CR11252A patent/CR11252A/es unknown
- 2010-02-04 IL IL20373410A patent/IL203734A/en not_active IP Right Cessation
- 2010-02-08 ZA ZA2010/00912A patent/ZA201000912B/en unknown
- 2010-02-08 EC ECSP109944 patent/ECSP109944A/es unknown
- 2010-03-01 MA MA32659A patent/MA31685B1/fr unknown
-
2013
- 2013-08-27 US US14/011,110 patent/US9115134B2/en not_active Expired - Fee Related
- 2013-12-13 CY CY20131101130T patent/CY1114906T1/el unknown
-
2015
- 2015-06-04 US US14/731,246 patent/US9321777B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2010001593A (es) | Nuevos derivados de 6-triazolopiridazina-sulfanil benzotiazol y bencimidazol, su proceso de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y nuevo uso principalmente como inhibidores de met. | |
| MX2010004293A (es) | Derivados de 6-aril/heteroalquiloxi benzotiazol y bencimidazol, su procedimiento de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y nuevo uso principalmente como inhibidores de cmet. | |
| BRPI0921701B8 (pt) | Cefarosporina tendo um grupo catecol, seu uso e composição farmacêutica que a compreende | |
| EA201071019A1 (ru) | Кристаллические формы производных фениламинопиримидина | |
| EA200701176A1 (ru) | Новые соединения нафталина, способ их получения и фармацевтические композиции, содержащие их | |
| NO20084005L (no) | Aminderivater | |
| CY1110034T1 (el) | Παραγωγα 1,2,4,5-τετραϋδρο-3h-βενζαζεπινων, μεθοδος παρασκευης αυτων και οι φαρμακευτικες συνθεσεις που τα περιεχουν | |
| AR063988A1 (es) | Derivados heterociclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| CY1111367T1 (el) | Νεα παραγωγα της διοσμετινης, η μεθοδος παρασκευης τους και οι φαρμακευτικες συνθεσεις που τα περιεχουν | |
| WO2008099072A3 (fr) | Nouveaux derives de 2, 4-dianilinopyrimidines, leur preparation, a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk | |
| GEP20115166B (en) | 2-ARYLINDOLE DERIVATIVES AS mPGES-I INHIBITORS | |
| NO20081169L (no) | Nye camptothecinanalogforbindelser, en fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende dem | |
| CY1109637T1 (el) | Νεα τρικυκλικα παραγωγα, η μεθοδος παρασκευης τους και οι φαρμακευτικες συνθεσεις που τα περιεχουν | |
| TNSN07395A1 (en) | Novel phenyl-pyridinyl-piperazine derivatives, a method for the production thereof and pharmaceutical compositions containing said derivatives | |
| PH12013501856A1 (en) | Novel octahydrothienoquinoline derivative, pharmaceutical composition comprising derivative, and use of these | |
| TW200714598A (en) | Urea derivatives, methods for their manufacture, and uses therefor | |
| NO20081944L (no) | Nye benzimidazol- og benzothiazolderivater, fremgangsmate for fremstilling, anvendelse derav som legemiddel, samt farmasoytiske sammensetninger og ny anvendelse spesielt som C-Met inhibitorer | |
| CO6420339A2 (es) | Derivados de 6-(6-sustituido-triazolopiridacina-sulfanil) 5-fluoro-benzotiazoles y 5-fluoro-bencimidazoles : preparación, aplicación como medicamentos y utilización como inhibidores de met | |
| PH12014501625A1 (en) | Novel 6-triazolopyridazinesulfanyl benzothiazole and benzimidazole derivatives, method for production thereof and application as medicaments and pharmaceutical compositions and novel use as met inhibitors | |
| AR075250A1 (es) | Derivados de 6-(triazolopiridazinsulfanil sustituido en 6-nh)benzotiazoles y bencimidazoles; preparacion, aplicacion como medicamentos y utilizacion como inhibidores de met. | |
| MX2009004006A (es) | Derivados de indol novedosos, proceso para la preparacion de los mismos y composiciones farmaceuticas que los contienen. | |
| DE502006008710D1 (de) | Substituierte tetrahydroisochinoline als mmp-inhibitoren, verfahren zu ihrer herstellung und ihre verwendung als medikament | |
| BR0315996A (pt) | Derivados de 2,3-dihidro-4(1h)-piridinonas, seu processo de preparo e as composições farmacêuticas que os contêm | |
| UA91646C2 (ru) | Соединения индола, способ их получения и фармацевтическая композиция (варианты), которая их содержит | |
| NO20074347L (no) | Nye heterocykliske oksimforbindelser, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende dem |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |